The Brazilian drug market has traded BRL 106,78 billion in 2022, equivalent to USD 20,70 billion [Pharmacy Channel), net value - average discount of 37,58%], according to surveys by IQVIA consultancy. There was an increase of 16,95% in BRL, compared to the previous year, representing approximately 2% of the world market, being the 10th in revenue in the ranking of the 20 main economies. In Latin America, it is the main market, ahead of Mexico, Colombia and Argentina.
English version of the document presenting the current global regulatory landscape for products falling under the category of advanced therapies, featuring high product complexity.
English version of the document aimed at presenting the main international references regarding the criteria and usage of RWD (Real World Data) and RWE (Real World Evidence) in regulatory decisions.
The Sindusfarma Annual Activity Report 2022, in Portuguese, records the achievements of the organization in all of its areas of operation.
“Advanced Therapies” magazine presents the main topics discussed by experts and authorities at the “Advanced Therapies Forum – Generating Value to the Patient and Health System Journey”, held by Sindusfarma in August/September 2021.
In the Gene and Advanced Therapies: Creating Value in the Patient Journey and in the Health System Forum, held by the Syndicate of the Pharmaceutical Industries (Sindusfarma) and the National Health Surveillance Agency (Anvisa) on October 23 and 24, 2019, in the agency’s auditorium in Brasilia, public managers, physicians, national and international researchers, congressmen, and healthcare leaders shared experiences in Brazil and in other countries. They discussed various aspects related to the theme, such as regulation, clinical research, diagnosis, legislation, financing, and sustainability of the system.
Committed to reducing social inequality and overcoming institutional and structural racism in Brazil, Sindusfarma prepared a “Guideline for the Advancement of Racial Equity in the Pharmaceutical Sector”.
Written by Sindusfarma's Diversity Working Group, the document was approved by the entity's Board of Directors last December. Sindusfarma's GT Diversity has been operating since 2021.
English version of the post about the Brazilian General Data Protection Act (LGPD), produced by the partnership between Sindusfarma and Interfarma. The content was developed based on the consultancy work of the law firm Chenut Oliveira Santiago Advogados, under the leadership of Fernando Santiago.
Published in September/2020
English version of the consolidated and revised summary of the discussions from the four therapy panels of the Clinical Research Week, which took place between May 18th and 21st of this year, recorded for the International Day of Clinical Research.
Published in November/2018
Gladys Silva, Juliana Rahal Cabello e Tatiana Gaban
English version of the Good Practices in Medical Information
Bilingual book (Portuguese-English) commemorating the 85th anniversary of Sindusfarma. The work outlines a broad panel of industries, facilities, equipment, work environments, medicines, advertisements and publications that illustrate the rich trajectory of the sector and its significant participation in the life of the country.
Published in October/2019
Hernandez, Vivian; Pizani, Karen; Yoshikawa, Pedro S.; Carvalheiro, Tatiane; Abreu, Livia M.; Grunthal, Fernanda B; Coelho, Izabel; Pereira, Fernando; com o apoio do Sindicato da Indústria de Produtos Farmacêuticos (SINDUSFARMA)
Published in November/2017
Cecilia Diaz, Juliana Perlow, Lilian Sabeh e Luciana Moraes
English version of the document that is intended for companies associated with Sindusfarma and whose purpose is to understand the impact of the Brazilian General Data Protection Act (LGPD) on the Pharmacovigilance Processes carried out by them.
English version of "Understanding and application of Circular Letter Nº 13/2020-CONEP/SECNS/MS".The document aims to assist Clinical Research Centers and Sponsors in the stages of the process of preparing and submitting the requirements of Circular Letter Nº. 13/2020-CONEP/SECNS/MS to the Research Ethics Committees (CEPs).
The book 'Symposium New Pharmaceutical Frontiers - A Pioneer Project' documents the topics and speakers presented at the meetings from its inaugural edition in 2012 through 2017.